Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC
NCT ID: NCT06435013
Last Updated: 2024-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
208 participants
OBSERVATIONAL
2023-12-01
2024-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
NCT03775395
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
NCT04044651
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
NCT06333561
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
NCT05029973
HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
NCT03869034
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LenHAP
Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
Lenvatinib
Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
BevHAP
Bevacizumab combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lenvatinib
Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shi Ming
Ming Shi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Center Sun Yat-sen University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LenBev-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.